1. Home
  2. RCKT vs UROY Comparison

RCKT vs UROY Comparison

Compare RCKT & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • UROY
  • Stock Information
  • Founded
  • RCKT 1999
  • UROY 2017
  • Country
  • RCKT United States
  • UROY Canada
  • Employees
  • RCKT N/A
  • UROY N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • UROY
  • Sector
  • RCKT Health Care
  • UROY
  • Exchange
  • RCKT Nasdaq
  • UROY Nasdaq
  • Market Cap
  • RCKT 328.6M
  • UROY 336.8M
  • IPO Year
  • RCKT N/A
  • UROY N/A
  • Fundamental
  • Price
  • RCKT $3.28
  • UROY $3.15
  • Analyst Decision
  • RCKT Buy
  • UROY Strong Buy
  • Analyst Count
  • RCKT 13
  • UROY 2
  • Target Price
  • RCKT $12.96
  • UROY $4.00
  • AVG Volume (30 Days)
  • RCKT 6.0M
  • UROY 2.6M
  • Earning Date
  • RCKT 08-07-2025
  • UROY 07-16-2025
  • Dividend Yield
  • RCKT N/A
  • UROY N/A
  • EPS Growth
  • RCKT N/A
  • UROY N/A
  • EPS
  • RCKT N/A
  • UROY N/A
  • Revenue
  • RCKT N/A
  • UROY $11,285,840.00
  • Revenue This Year
  • RCKT N/A
  • UROY $228.36
  • Revenue Next Year
  • RCKT $108.43
  • UROY N/A
  • P/E Ratio
  • RCKT N/A
  • UROY N/A
  • Revenue Growth
  • RCKT N/A
  • UROY N/A
  • 52 Week Low
  • RCKT $2.19
  • UROY $1.43
  • 52 Week High
  • RCKT $22.01
  • UROY $3.30
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 51.17
  • UROY 65.88
  • Support Level
  • RCKT $2.88
  • UROY $2.51
  • Resistance Level
  • RCKT $3.74
  • UROY $2.87
  • Average True Range (ATR)
  • RCKT 0.27
  • UROY 0.16
  • MACD
  • RCKT 0.02
  • UROY 0.05
  • Stochastic Oscillator
  • RCKT 35.43
  • UROY 82.05

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About UROY Uranium Royalty Corp.

Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.

Share on Social Networks: